Oruka Therapeutics, Inc. announced progress in its clinical programs with ORKA-001 and ORKA-002, targeting chronic skin diseases like psoriasis. The company completed dosing in a Phase 1 trial for ...
Roivant Sciences Ltd. (NASDAQ: ROIV) set out its long-term vision on Tuesday during its Investor Day, outlining accelerated timelines and expanded commercial ambitions across several late-stage ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Oklo Inc. (OKLO) (“Oklo”), an advanced nuclear technology company, announced today that the U.S. Nuclear Regulatory Commission (NRC) has accepted for review its ...
IRVINE, CA, UNITED STATES, June 9, 2025 /EINPresswire.com/ -- Qalitex Laboratories acknowledged the continued importance of stability testing in regulatory ...
Oklo (NYSE:OKLO) +2.1% pre-market Tuesday after saying the U.S. Nuclear Regulatory Commission has accepted for review its Principal Design Criteria topical report under an accelerated timeline. The ...